Surrozen, Inc.

We are a biotechnology company focused on discovering and developing product candidates that selectively adjust the Wnt pathway, which is crucial for tissue repair. Our primary focus is ophthalmology, where Wnt signaling is vital for retinal vascular integrity, barrier function, and tissue maintenance. We are located in South San Francisco, California. Our goal is to revolutionize the treatment of serious eye diseases by fully utilizing the Wnt pathway. Based on the foundational work of our founders and scientific advisors who identified the Wnt gene and its key regulators, we have made significant discoveries. These discoveries allow us to rapidly and flexibly create tissue-targeted treatments that modulate Wnt signaling, forming the basis of our ophthalmology portfolio and research programs. These programs aim to restore tissue structure and function in serious eye diseases with significant unmet medical needs. Our main product candidates are multi-specific, antibody-based treatments that imitate natural Wnt proteins, which activate and enhance the Wnt pathway. Wnt signaling is essential for tissue maintenance and regeneration throughout the body. Our current development efforts are concentrated on ophthalmology because the Wnt pathway's biology is clinically proven in this area, and localized delivery allows for controlled therapeutic modulation. Our strategy involves identifying diseases responsive to Wnt modulation, designing tissue-selective treatments, evaluating mechanisms that complement Wnt signaling, and advancing candidates into clinical development for specific ophthalmic conditions with high unmet need. Our approach and platform technologies have led to the discovery and advancement of multiple product candidates. We believe ophthalmology indications are particularly suitable for Wnt modulating therapeutics due to strong genetic and biological validation and the need for methods to restore tissue structure and function.